75 related articles for article (PubMed ID: 8310673)
1. [Interferon-alfa in the treatment of myeloproliferative diseases].
Adam Z
Vnitr Lek; 1993 Dec; 39(12):1210-8. PubMed ID: 8310673
[TBL] [Abstract][Full Text] [Related]
2. [Interferon alfa in the treatment of monoclonal gammopathies].
Adam Z
Vnitr Lek; 1994 Feb; 40(2):122-6. PubMed ID: 8140761
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM;
Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462
[TBL] [Abstract][Full Text] [Related]
4. [Interferon-alpha in the treatment of myeloproliferative syndromes].
Ballarino P; Castello G; Lerza R
Recenti Prog Med; 1994 Nov; 85(11):546-50. PubMed ID: 7855389
[TBL] [Abstract][Full Text] [Related]
5. [Interferons. Interferons alpha and gamma: indications in systemic diseases].
Blétry O; Papo T
Ann Med Interne (Paris); 1993; 144(8):557-62. PubMed ID: 8179244
[TBL] [Abstract][Full Text] [Related]
6. [Interferon alfa in the treatment of hairy cell leukemia].
Adam Z
Vnitr Lek; 1994 Mar; 40(3):199-202. PubMed ID: 8184577
[TBL] [Abstract][Full Text] [Related]
7. [Interferon alfa in the treatment of malignant lymphomas].
Adam Z
Vnitr Lek; 1994 Apr; 40(4):255-8. PubMed ID: 8184589
[TBL] [Abstract][Full Text] [Related]
8. [Retrospective multicenter study of the efficacy of interferon alpha in chronic hepatitis C].
Salmerón J; Martín-Vivaldi R; Palacios A; Nogueras F; Aguilar J; de la Mata M; Andrade R; Puertas M; Sánchez H; Santalla F; Bellot V; Quintero D; Díaz F; Pérez Durán MA; Romero M; Luna JD; Ruiz-Extremera A
Med Clin (Barc); 1996 Nov; 107(18):689-92. PubMed ID: 9082077
[TBL] [Abstract][Full Text] [Related]
9. [Predictive value of a rapid negativity of serum virus C viremia during treatment with interferon alpha in patients with chronic hepatitis C].
Moulin V; Harzic M; Doll J; Dubeaux B; Ghnassia JC; Andrieu J
Pathol Biol (Paris); 1996 May; 44(5):468-72. PubMed ID: 8758497
[TBL] [Abstract][Full Text] [Related]
10. [Myeloproliferative diseases].
Adam Z; Vorlícek J; Matýsková M
Vnitr Lek; 1996 Oct; 42(10):710-6. PubMed ID: 8975464
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases].
Coutant G; Blétry O; Prin L; Hauteville D; de Puyfontaine O; Abgrall JF; Godeau P
Ann Med Interne (Paris); 1993; 144(4):243-50. PubMed ID: 8368716
[TBL] [Abstract][Full Text] [Related]
12. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Nielsen I; Hasselbalch HC
Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
[TBL] [Abstract][Full Text] [Related]
13. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
14. [Interferon alpha in the treatment of polycythemia vera in a 13-year-old girl].
Ołpiński M; Jakieła T; Korczowski R
Pediatr Pol; 1996 Aug; 71(8):705-7. PubMed ID: 8927476
[TBL] [Abstract][Full Text] [Related]
15. Complete molecular remission after interferon alpha treatment in a case of 8p11 myeloproliferative syndrome.
Zhou L; Fu W; Yuan Z; Hou J
Leuk Res; 2010 Nov; 34(11):e306-7. PubMed ID: 20650528
[No Abstract] [Full Text] [Related]
16. [Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].
Tichelli A; Gratwohl A; Delacrétaz F; Dazzi H; Stebler C; Wernli M; Holdener EE; Nissen C; Speck B
Schweiz Med Wochenschr; 1989 Sep; 119(39):1347-52. PubMed ID: 2799342
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of side effects of interferon-alpha in 72 patients treated for chronic active hepatitis C].
Duché A; Decocq G; Capron-Chivrac D; Andréjak M
Therapie; 1995; 50(5):419-23. PubMed ID: 8571279
[TBL] [Abstract][Full Text] [Related]
18. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
19. [Cytokine spectrum in patients with chronic hepatitis C in the treatment with interferon-alpha drugs].
Sobchak DM; Korochkina OV; Monakova EA
Ter Arkh; 2005; 77(2):70-2. PubMed ID: 15807457
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
Thiele J; Kvasnicka HM
Ann Hematol; 2003 Mar; 82(3):148-52. PubMed ID: 12634946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
